Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206011 | 0.85 | RET (0.41) | HDAC1HDAC2HDAC3RETCHRM3 | |
| SCHEMBL20069514 | 0.84 | RET (0.38) | HDAC1HDAC2HDAC3RETCHRM3 | |
| SCHEMBL20069513 | 0.81 | OPRM1 (0.43) | RET | |
| SCHEMBL20069722 | 0.80 | RET (0.43) | HDAC1HDAC2HDAC3RETCHRM3 | |
| SCHEMBL20069701 | 0.77 | RET (0.37) | HDAC1HDAC2HDAC3RETCHRM3 | |
| SCHEMBL20069155 | 0.77 | RET (0.38) | HDAC1HDAC2RET | |
| SCHEMBL20070374 | 0.74 | EPHX1 (0.42) | RETCHRM3SCN1ASCN2ASCN3A | |
| SCHEMBL17285996 | 0.72 | HDAC1 (0.39) | HDAC1HDAC2HDAC3CHRM3KDM1A | |
| SCHEMBL10191097 | 0.71 | CTSL (0.48) | SCN1ASCN2ASCN3A | |
| SCHEMBL20069704 | 0.71 | RET (0.37) | RETSCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HDAC1 1094/4885HDAC2 1936/4885HDAC3 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.